HK1137758A1 - Inhibitors of akt activity akt - Google Patents
Inhibitors of akt activity aktInfo
- Publication number
- HK1137758A1 HK1137758A1 HK10102928.1A HK10102928A HK1137758A1 HK 1137758 A1 HK1137758 A1 HK 1137758A1 HK 10102928 A HK10102928 A HK 10102928A HK 1137758 A1 HK1137758 A1 HK 1137758A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- akt
- inhibitors
- activity
- akt activity
- activity akt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87319806P | 2006-12-06 | 2006-12-06 | |
US88066107P | 2007-01-16 | 2007-01-16 | |
US96787207P | 2007-09-06 | 2007-09-06 | |
PCT/US2007/024722 WO2008070016A2 (en) | 2006-12-06 | 2007-12-03 | Inhibitors of akt activity |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1137758A1 true HK1137758A1 (en) | 2010-08-06 |
Family
ID=39492823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10102928.1A HK1137758A1 (en) | 2006-12-06 | 2010-03-19 | Inhibitors of akt activity akt |
Country Status (30)
Country | Link |
---|---|
US (3) | US7576209B2 (zh) |
EP (1) | EP2104669B1 (zh) |
JP (2) | JP4431636B1 (zh) |
KR (1) | KR101110598B1 (zh) |
CN (1) | CN101600706B (zh) |
AR (1) | AR064010A1 (zh) |
AU (1) | AU2007328286B2 (zh) |
BR (1) | BRPI0719580A2 (zh) |
CA (1) | CA2670760C (zh) |
CL (1) | CL2007003495A1 (zh) |
CO (1) | CO6190528A2 (zh) |
CR (1) | CR10851A (zh) |
EA (1) | EA016195B1 (zh) |
EC (1) | ECSP099376A (zh) |
ES (1) | ES2527567T3 (zh) |
GE (1) | GEP20125469B (zh) |
GT (1) | GT200900146A (zh) |
HK (1) | HK1137758A1 (zh) |
HN (1) | HN2009001112A (zh) |
IL (2) | IL198826A (zh) |
MA (1) | MA31027B1 (zh) |
MX (1) | MX2009006052A (zh) |
NI (1) | NI200900106A (zh) |
NO (1) | NO20092569L (zh) |
NZ (2) | NZ595829A (zh) |
PE (1) | PE20081341A1 (zh) |
SV (1) | SV2009003283A (zh) |
TN (1) | TN2009000224A1 (zh) |
TW (1) | TWI386410B (zh) |
WO (2) | WO2008070041A2 (zh) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100047338A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
JP5055494B2 (ja) * | 2005-06-10 | 2012-10-24 | メルク・シャープ・エンド・ドーム・コーポレイション | Akt活性阻害剤 |
AU2007327992A1 (en) * | 2006-12-06 | 2008-06-12 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
AR064010A1 (es) * | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
AU2009255358A1 (en) * | 2008-06-03 | 2009-12-10 | Msd K.K. | Inhibitors of Akt activity |
JP2011522047A (ja) * | 2008-06-03 | 2011-07-28 | メルク・シャープ・エンド・ドーム・コーポレイション | Akt活性の阻害剤 |
US8524730B2 (en) | 2008-07-04 | 2013-09-03 | Msd K.K. | Spirochromanone carboxylic acids |
KR101354763B1 (ko) | 2008-08-25 | 2014-01-22 | 아이알엠 엘엘씨 | 헷지호그 경로 조절제 |
DE102008043724A1 (de) * | 2008-11-13 | 2010-05-20 | Biotronik Vi Patent Ag | Erhöhung der Effizienz pharmazeutische Wirkstoffe-freisetzender Medizinprodukte durch Kombination mit einem Inhibitor des Transportproteins P-Glycoprotein |
JP2012516847A (ja) * | 2009-02-02 | 2012-07-26 | メルク・シャープ・エンド・ドーム・コーポレイション | Akt活性の阻害剤 |
CN102686600A (zh) | 2009-02-05 | 2012-09-19 | 托凯药业股份有限公司 | 甾体cyp17抑制剂/抗雄激素物质的新型药物前体 |
EP2403339B1 (en) * | 2009-03-06 | 2017-01-18 | Merck Sharp & Dohme Corp. | Combination cancer therapy with an akt inhibitor and other anticancer agents |
EP2405756B1 (en) | 2009-03-12 | 2013-07-03 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
JP5567136B2 (ja) | 2009-09-08 | 2014-08-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 4−置換ピリジン−3−イル−カルボキサミド化合物及び使用方法 |
US8546376B2 (en) | 2009-09-18 | 2013-10-01 | Almac Discovery Limited | Pharmaceutical compounds |
GB0919380D0 (en) | 2009-11-04 | 2009-12-23 | Almac Discovery Ltd | Pharmaceutical compouds |
GB0922589D0 (en) | 2009-12-23 | 2010-02-10 | Almac Discovery Ltd | Pharmaceutical compounds |
WO2011130921A1 (en) * | 2010-04-23 | 2011-10-27 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
EP2572199B1 (en) | 2010-05-21 | 2017-03-08 | Novartis AG | Combination |
EP2593451B1 (en) | 2010-07-12 | 2015-08-19 | Bayer Intellectual Property GmbH | Substituted imidazo[1,2-a]pyrimidines and -pyridines |
JP2013530250A (ja) | 2010-07-13 | 2013-07-25 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 二環式ピリミジン化合物 |
CN103384670B (zh) * | 2010-07-28 | 2016-05-25 | 拜耳知识产权有限责任公司 | 取代的咪唑并[1,2-b]哒嗪 |
CA2821777A1 (en) * | 2010-12-16 | 2012-06-21 | Bayer Intellectual Property Gmbh | Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway |
AU2012205601B2 (en) * | 2011-01-11 | 2016-03-24 | Novartis Ag | Combination |
WO2012137870A1 (ja) | 2011-04-06 | 2012-10-11 | 大鵬薬品工業株式会社 | 新規イミダゾオキサジン化合物又はその塩 |
DK2694510T3 (en) | 2011-04-07 | 2016-01-18 | Bayer Ip Gmbh | IMIDAZOPYRIDAZINER AS AKT kinase inhibitors |
US8815854B2 (en) | 2011-06-24 | 2014-08-26 | Arqule, Inc. | Substituted imidazopyridinyl compounds |
BR112013033182A2 (pt) * | 2011-06-24 | 2016-09-06 | Arqule Inc | compostos imidazopiridinil-aminopiridina substituída |
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
CN104066736B (zh) | 2012-01-10 | 2017-03-08 | 拜耳知识产权有限责任公司 | 作为akt激酶抑制剂的取代的吡唑并嘧啶 |
CA2860723A1 (en) | 2012-01-10 | 2013-07-18 | Bayer Intellectual Property Gmbh | Substituted imidazopyrazines as akt kinase inhibitors |
CA2865202A1 (en) | 2012-01-20 | 2013-07-25 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Enhanced glycemic control using ad36e4orf1 and akt1 inhibitor |
GB201205164D0 (en) | 2012-03-23 | 2012-05-09 | Almac Discovery Ltd | Pharmaceutical compounds |
NO2868660T3 (zh) | 2012-07-02 | 2018-05-26 | ||
CA2904170A1 (en) | 2013-03-14 | 2014-09-25 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
KR20160099081A (ko) | 2013-07-26 | 2016-08-19 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조합 방법 |
CN105636594A (zh) | 2013-08-12 | 2016-06-01 | 托凯药业股份有限公司 | 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物 |
AU2014330779A1 (en) | 2013-10-01 | 2016-04-07 | Novartis Ag | Combination |
MX2016004265A (es) | 2013-10-01 | 2016-07-08 | Novartis Ag | Combinacion. |
WO2015094928A1 (en) * | 2013-12-17 | 2015-06-25 | Merck Sharp & Dohme Corp. | Liposomal compositions for allosteric akt inhibitors |
AU2015211021B2 (en) | 2014-01-28 | 2020-07-02 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
CN106456642A (zh) | 2014-03-12 | 2017-02-22 | 诺华股份有限公司 | 含btk抑制剂与akt抑制剂的组合 |
ES2872552T3 (es) | 2014-03-17 | 2021-11-02 | Merck Sharp & Dohme | Nanopartículas poliméricas y métodos de preparación y de uso de las mismas |
WO2016136928A1 (ja) | 2015-02-27 | 2016-09-01 | 大鵬薬品工業株式会社 | イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法 |
FR3033499A1 (fr) * | 2015-03-11 | 2016-09-16 | Centre Leon-Berard | Composition pour le traitement des tumeurs neuroendocrines pancreatiques |
EP3372601B1 (en) * | 2015-10-22 | 2022-09-21 | Mitsubishi Tanabe Pharma Corporation | Novel bicyclic heterocyclic compound |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
CN108426971B (zh) * | 2018-03-09 | 2020-03-20 | 浙江中一检测研究院股份有限公司 | 一种快速检测水中微囊藻毒素的方法 |
JP2023525758A (ja) * | 2020-05-08 | 2023-06-19 | ジョージアミューン・インコーポレイテッド | Akt3モジュレーターおよびその使用方法 |
WO2024083716A1 (en) | 2022-10-17 | 2024-04-25 | Astrazeneca Ab | Combinations of a serd for the treatment of cancer |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE400274T1 (de) * | 2001-04-10 | 2008-07-15 | Merck & Co Inc | Hemmstoffe der akt aktivität |
WO2002083064A2 (en) * | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | A method of treating cancer |
US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
CA2480800C (en) * | 2002-04-08 | 2008-09-23 | Mark T. Bilodeau | Inhibitors of akt activity |
AU2003230802B2 (en) * | 2002-04-08 | 2007-08-09 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
AU2003226250B2 (en) * | 2002-04-08 | 2007-08-16 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
AU2003226271B2 (en) * | 2002-04-08 | 2007-10-18 | Merck Sharp & Dohme Corp. | Fused quinoxaline derivatives as inhibitors of Akt activity |
JP2006507299A (ja) * | 2002-10-30 | 2006-03-02 | メルク エンド カムパニー インコーポレーテッド | Akt活性の阻害薬 |
CA2522430A1 (en) * | 2003-04-24 | 2004-11-11 | Merck & Co., Inc. | Inhibitors of akt activity |
ATE446752T1 (de) * | 2003-04-24 | 2009-11-15 | Merck & Co Inc | Hemmer der akt aktivität |
US7304063B2 (en) * | 2003-04-24 | 2007-12-04 | Merck & Co., Inc. | Inhibitors of Akt activity |
ATE512957T1 (de) * | 2003-04-24 | 2011-07-15 | Merck Sharp & Dohme | Hemmer der akt aktivität |
WO2005007099A2 (en) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
JP2007008816A (ja) * | 2003-10-15 | 2007-01-18 | Ube Ind Ltd | 新規イソキノリン誘導体 |
TWI344961B (en) * | 2003-10-15 | 2011-07-11 | Ube Industries | Novel indazole derivative |
US7750151B2 (en) | 2004-04-09 | 2010-07-06 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
EP1737843B1 (en) * | 2004-04-09 | 2011-02-23 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
AU2005290081B2 (en) * | 2004-08-23 | 2010-12-02 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
EP1824849A4 (en) * | 2004-12-02 | 2009-09-30 | Merck & Co Inc | INHIBITORS OF AKT ACTIVITY |
CN101242834A (zh) | 2004-12-15 | 2008-08-13 | 默克公司 | Akt活性抑制剂 |
EP1850843A4 (en) * | 2005-02-14 | 2012-02-15 | Merck Sharp & Dohme | ACTIVITY INHIBITORS OF AKT |
JP2008535915A (ja) * | 2005-04-12 | 2008-09-04 | メルク エンド カムパニー インコーポレーテッド | Akt活性の阻害剤 |
JP5055494B2 (ja) | 2005-06-10 | 2012-10-24 | メルク・シャープ・エンド・ドーム・コーポレイション | Akt活性阻害剤 |
WO2007087250A2 (en) * | 2006-01-23 | 2007-08-02 | Amira Pharmaceuticals, Inc. | Tricyclic inhibitors of 5-lipoxygenase |
AR064010A1 (es) * | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
WO2008124083A2 (en) * | 2007-04-05 | 2008-10-16 | Amgen Inc. | Aurora kinase modulators and method of use |
-
2007
- 2007-11-28 AR ARP070105281A patent/AR064010A1/es active IP Right Grant
- 2007-11-29 TW TW096145487A patent/TWI386410B/zh not_active IP Right Cessation
- 2007-11-30 PE PE2007001698A patent/PE20081341A1/es not_active Application Discontinuation
- 2007-12-03 CN CN2007800509679A patent/CN101600706B/zh not_active Expired - Fee Related
- 2007-12-03 WO PCT/US2007/024772 patent/WO2008070041A2/en active Application Filing
- 2007-12-03 KR KR1020097011729A patent/KR101110598B1/ko not_active IP Right Cessation
- 2007-12-03 NZ NZ595829A patent/NZ595829A/xx not_active IP Right Cessation
- 2007-12-03 CA CA2670760A patent/CA2670760C/en not_active Expired - Fee Related
- 2007-12-03 WO PCT/US2007/024722 patent/WO2008070016A2/en active Application Filing
- 2007-12-03 GE GEAP200711349A patent/GEP20125469B/en unknown
- 2007-12-03 EA EA200970542A patent/EA016195B1/ru not_active IP Right Cessation
- 2007-12-03 MX MX2009006052A patent/MX2009006052A/es active IP Right Grant
- 2007-12-03 BR BRPI0719580-0A patent/BRPI0719580A2/pt active Search and Examination
- 2007-12-03 EP EP07862428.5A patent/EP2104669B1/en active Active
- 2007-12-03 AU AU2007328286A patent/AU2007328286B2/en not_active Ceased
- 2007-12-03 NZ NZ577470A patent/NZ577470A/en not_active IP Right Cessation
- 2007-12-03 ES ES07862428.5T patent/ES2527567T3/es active Active
- 2007-12-03 JP JP2009540243A patent/JP4431636B1/ja not_active Expired - Fee Related
- 2007-12-04 CL CL200703495A patent/CL2007003495A1/es unknown
- 2007-12-04 US US11/999,234 patent/US7576209B2/en active Active
-
2009
- 2009-05-19 IL IL198826A patent/IL198826A/en not_active IP Right Cessation
- 2009-05-28 CO CO09054952A patent/CO6190528A2/es active IP Right Grant
- 2009-05-29 NI NI200900106A patent/NI200900106A/es unknown
- 2009-06-01 EC EC2009009376A patent/ECSP099376A/es unknown
- 2009-06-02 HN HN2009001112A patent/HN2009001112A/es unknown
- 2009-06-02 GT GT200900146A patent/GT200900146A/es unknown
- 2009-06-03 SV SV2009003283A patent/SV2009003283A/es unknown
- 2009-06-03 TN TNP2009000224A patent/TN2009000224A1/fr unknown
- 2009-06-05 JP JP2009135908A patent/JP5364454B2/ja not_active Expired - Fee Related
- 2009-06-09 CR CR10851A patent/CR10851A/es not_active Application Discontinuation
- 2009-06-10 US US12/482,095 patent/US20090253734A1/en not_active Abandoned
- 2009-06-26 MA MA32047A patent/MA31027B1/fr unknown
- 2009-07-06 NO NO20092569A patent/NO20092569L/no not_active Application Discontinuation
-
2010
- 2010-03-19 HK HK10102928.1A patent/HK1137758A1/xx not_active IP Right Cessation
- 2010-04-21 IL IL205220A patent/IL205220A0/en not_active IP Right Cessation
-
2011
- 2011-03-11 US US13/046,322 patent/US8288407B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1137758A1 (en) | Inhibitors of akt activity akt | |
HK1132676A1 (zh) | 活性的抑制劑 | |
HK1225722A1 (zh) | 激酶活性抑製劑 | |
HRP20130429T1 (en) | Inhibitors of akt activity | |
EP1968568A4 (en) | HEMMER OF NUTS ACTIVITY | |
AP2008004442A0 (en) | Inhibitors of AKT activity | |
EP1850843A4 (en) | ACTIVITY INHIBITORS OF AKT | |
EP2303269A4 (en) | HAMMER OF ACT ACTIVITY | |
EP1871376A4 (en) | INHIBITOR OF AKT ACTIVITY | |
EP2114388A4 (en) | INHIBITORS OF AKT'S ACTIVITY | |
EP1720855A4 (en) | HEMMER OF ACT ACTIVITY | |
EP1784175A4 (en) | INHIBITORS OF ACT ACTIVITY | |
EP1737861A4 (en) | INHIBITORS OF AKT ACTIVITY | |
EP1827436A4 (en) | ACTIVITY INHIBITORS AKT | |
EP2391623A4 (en) | INHIBITORS OF AKT ACTIVITY | |
IL209488A0 (en) | Inhibitors of akt activity | |
EP2134175A4 (en) | HAMMER OF ACT ACTIVITY | |
EP2120951A4 (en) | INHIBITORS OF AKT ACTIVITY | |
EP2406250A4 (en) | HAMMER OF ACT ACTIVITY | |
EP2303852A4 (en) | ACTIVITY INHIBITORS AKT | |
EP2306825A4 (en) | HAMMER OF ACT ACTIVITY | |
EP1824849A4 (en) | INHIBITORS OF AKT ACTIVITY | |
EP2405756A4 (en) | HAMMER OF ACT ACTIVITY | |
EP2516435B8 (en) | Inhibitors of akt activity | |
EP1948185A4 (en) | INHIBITORS OF AKT ACTIVITY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20171203 |